Modulation of phencyclidine-induced changes in locomotor activity and patterns in rats by serotonin

European Journal of Pharmacology

Volumn 343, Issue 2-3, 1998, Pages 135-143

  Krebs Thomson, Kirsten ^a   Lehmann Masten, Virginia ^a   Naiem, Shahrouz ^a   Paulus, Martin P ^a   Geyer, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 HT2 receptor; DOI(1(2,5 dimethoxy 4 iodophenyl) 2 aminopropane; Ketanserin; Locomotion; Phencyclidine; Rat

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; GLUTAMATE RECEPTOR; KETANSERIN; PHENCYCLIDINE; SEROTONIN 2 AGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; LOCOMOTION; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

AMPHETAMINES; ANIMALS; KETANSERIN; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STEREOTYPED BEHAVIOR;

EID: 0344835242     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01557-4     Document Type: Article

References (46)

1. Ali S.F., Newport G.D., Bracha H.S. Phencyclidine and (+)-MK-801-induced circling preference: Correlation with monoamine levels in striatum of the rat brain. Neurotoxicol. Teratol. 16:1994;335-342.
2. 2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse-implications for psychosis. J. Neural Transm. 100:1995;225-237.
3. Castellani S., Adams P.M. Effects of dopaminergic drugs on phencyclidine-induced behavior in the rat. Neuropharmacology. 20:1981;371-374.
4. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology. 120:1995;67-74.
5. Domino, E.F., Luby, E.D., 1981. Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: Domino, E.F. (Ed.), PCP (Phencyclidine): Historical and Current Perspectives. NPP Books, Ann Arbor, MI, pp. 400-418.
6. Fonnum F., Karlsen R.L., Mathe-Sorenssen P., Skrede K.K. Localization of neurotransmitters, particularly glutamate in hippocampus, septum, nucleus accumbens and superior colliculus. Prog. Brain Res. 51:1979;169-191.
7. Garey R.E. PCP (phencyclidine): An update. J. Psychedelic Drugs. 11:1979;265-275.
8. 3H -catecholamines by rat striatal and hypothalamic synaptosomes Life Sci. 18:1976;1105-1110.
9. Geyer, M.A., 1990. Approaches to the characterization of drug effects on locomotor activity in rodents. In: Adler, M.W., Cowan, A. (Eds.), Modern Methods in Pharmacology: Testing and Evaluation of Drugs of Abuse. Wiley-Liss, New York, pp. 81-99.
10. Geyer M.A., Russo P.V., Masten V.L. Multivariate assessment of locomotor behavior: Pharmacological and behavioral analyses. Pharmacol. Biochem. Behav. 25:1986;277-288.
11. Gleason S.D., Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzepine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology. 129:1997;79-84.
12. Glennon R.A., Raghupathi R., Bartyzel P., Teitler M., Leonhardt S. Binding of phenalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: Evidence for a lack of selectivity. J. Med. Chem. 35:1992;734-740.
13. Hernandez L., Auerbach S., Hoebel B.G. Phencyclidine (PCP) injected in the nucleus accumbens increases extracellular dopamine and serotonin as measured by microdialysis. Life Sci. 42:1988;1713-1723.
14. Hertel P., Mathé J.M., Nomikos G.G., Iurlo M., Mathé A.A., Svensson T.H. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav. Brain Res. 72:1996;103-114.
15. Hori T., Suzuki T., Baba A., Abe S., Yamamoto T., Moroji T., Shiraishi H. Effects of phencyclidine metabolites on serotonin uptake in rat brain. Neurosci. Lett. 209:1996;153-156.
16. Hoyer D., Schoeffter P. 5-HT receptors: Subtypes and second messengers. J. Receptor Res. 11:1991;197-214.
17. Jackson D.M., Johansson C., Lindgren L.-M., Bengtsson A. Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol. Biochem. Behav. 48:1994;465-471.
18. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 10:1991;1301-1308.
19. Javitt, D.C., Zukin, S.R., 1991b. Mechanisms of phencyclidine (PCP)-N-methyl-D-aspartate (NMDA) receptor interaction: Implications for schizophrenia. In: Tamminga, C.A., Schulz, S.C. (Eds.), Advances in Neuropsychiatry and Psychopharmacology, vol. 1: Schizophrenia Research. Raven Press, New York, NY, pp. 13-19.
20. Johnson K.M., Jones S.M. Neuropharmacology of phencyclidine: Basic mechanisms and therapeutic potential. Annu. Rev. Pharmacol. Toxicol. 30:1990;707-750.
21. Kameyama T., Sugimoto A., Yamaguchi K., Hiramatsu M., Furukawa H., Nabeshima T. The relationship between phencyclidine-induced stereotyped behavior and dopamine release using in vivo voltammetry. Res. Comm. Substance Abuse. 9:1988;89-105.
22. Kitaichi K., Yamada K., Hasegawa T., Furukawa H., Nabeshima T. Effects of risperidone on phencyclidine-induced behaviors: Comparison with haloperidol and ritanserin. Jpn. J. Pharmacol. 66:1994;181-189.
23. Lapin I.P., Rogawski M.A. Effects of D1 and D2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine in mice. Behav. Brain Res. 70:1995;145-151.
24. Lehmann-Masten V.D., Geyer M.A. Spatial and temporal patterning distinguishes the locomotor activating effects of dizocilpine and phencyclidine in rats. Neuropharmacology. 30:1991;629-636.
25. Lillrank S.M., O'Connor W.T., Oja S.S., Ungerstedt U. Systemic phencyclidine administration is associated with increased dopamine, GABA, and 5-HIAA levels in the dorsolateral striatum of conscious rats: An in vivo microdialysis study. J. Neural Transm. 95:1994;145-155.
26. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelly R. Study of a new schizophrenomimetic drug: Sernyl. A.M.A. Arch. Neurol. Psychiatry. 81:1959;363-369.
27. Luby E.D., Gottlieb J.S., Cohen B.D., Rosenbaum G., Domino E.F. Model psychoses and schizophrenia. Am. J. Psychiatry. 119:1962;61-65.
28. 2A receptors. Eur. J. Pharmacol. 280:1995;R9-R11.
29. Mogenson G.J., Nielsen M. A study of the contribution of hippocampal-accumbens-subpallidal projections to locomotor activity. Behav. Neur. Biol. 42:1984;38-51.
30. Mogenson G.J., Jones D.L., Yim C.Y. From motivation to action: Functional interface between the limbic system and the motor system. Prog. Neurobiol. 14:1980;69-97.
31. 2 receptors in the rat brain. Neuroscience. 54:1993;701-717.
32. Murray T.F., Horita A. Phencyclidine-induced stereotyped behavior in rats: Dose-response effects and antagonism by neuroleptics. Life Sci. 24:1979;2217-2226.
33. 2 receptor-mediated behavior in rats. Neurosci. Lett. 76:1987;335-338.
34. Nabeshima T., Yamaguchi K., Ishikawa K., Furukawa H., Kameyama T. Potentiation in phencyclidine-induced serotonin-mediated behaviors after intracerebroventricular administration of 5,7-dihydroxytryptamine in rats. J. Pharmacol. Exp. Ther. 243:1987;1139-1146.
35. Ögren S.O., Goldstein M. Phencyclidine- and dizocilpine-induced hyperlocomotion are differently mediated. Neuropsychopharmacology. 11:1994;167-177.
36. Palacios, J.M., Dietl, M.M., 1988. Autoradiographic studies of serotonin receptors. In: Sanders-Bush, E. (Ed.), The Serotonin Receptor. Humana Press, New York, pp. 89-138.
37. Paulus M.P., Geyer M.A. A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology. 104:1991;6-16.
38. Rao T.S., Kim H.S., Lehmann J., Martin L.L., Wood P.L. Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo. Life Sci. 45:1989;1065-1072.
39. 3H ]serotonin uptake in synaptosomal preparations from rat brain Biochem. Pharmacol. 26:1977;1435-1439.
40. Snyder S.H. Psychotogenic drugs as models for schizophrenia. Neuropsychopharmacology. 1:1988;197-199.
41. Steinpreis R.E., Salamone J.D. The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: A microdialysis and behavioral study. Brain Res. 612:1993;263-270.
42. 1-adrenoceptor antagonism. J. Clin. Psychopharmacol. 15:1995;11S-18S.
43. 1 receptors in phencyclidine-induced behavioral stimulation in rats. Clin. Neuropharmacol. 18:1995;64-71.
44. Wing L.L., Tapson G.S., Geyer M.A. 5-HT2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology. 100:1990;417-425.
45. Yamaguchi K., Nabeshima T., Kameyama T. Role of dopaminergic and serotonergic neuronal systems in the prefrontal cortex of rats in phencyclidine-induced behaviors. J. Pharmacobio-Dyn. 9:1986;987-996.
46. 2 receptors in reserpinized rats. Neuropharmacology. 26:1987;1489-1497.